Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinically available antischistosomal drugs.

A Davis

    Journal of Toxicology and Environmental Health
    |November 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    This study reviews antimonial and non-antimonial drugs for schistosomiasis treatment, detailing their efficacy, side effects, and contraindications for human schistosome infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Rubyspira, new genus and two new species of bone-eating deep-sea snails with ancient habits.

    The Biological bulletin·2010
    Same author

    Intra-uterine Aspiration.

    British medical journal·2010
    Same author

    Dicoumarin in Puerperal Thrombosis.

    British medical journal·2010
    Same author

    A simple double-focusing electrostatic ion beam deflector.

    The Review of scientific instruments·2010
    Same author

    Prevalence of Cysticercus bovis in Australian cattle.

    Australian veterinary journal·2010
    Same author

    Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.

    Haemophilia : the official journal of the World Federation of Hemophilia·2010

    Area of Science:

    • Medical Parasitology
    • Pharmacology
    • Tropical Medicine

    Background:

    • Schistosomiasis remains a significant global health concern, necessitating effective chemotherapeutic agents.
    • Current treatment options include antimonial and non-antimonial drugs with varying efficacy and safety profiles.

    Purpose of the Study:

    • To outline the indications, contraindications, and characteristics of available drugs for human schistosomiasis.
    • To compare the effectiveness and safety of different schistosomicidal compounds.

    Main Methods:

    • Review of clinically available antimonial drugs (e.g., antimony potassium tartrate, antimony dimercaptosuccinate).
    • Evaluation of non-antimonial drugs including niridazole, lucanthone hydrochloride, metrifonate, and hycanthone mesylate.
    • Analysis of drug administration routes, target schistosome species, and documented side effects.

    Related Experiment Videos

    Main Results:

    • Antimonial compounds like antimony potassium tartrate and antimony dimercaptosuccinate show broad-spectrum efficacy but are associated with severe side effects.
    • Non-antimonial drugs offer alternatives: niridazole is effective against all three species but has neuropsychiatric risks; metrifonate is specific for S. hematobium with good tolerance; hycanthone mesylate is effective against S. mansoni and S. hematobium but has contraindications and mutagenicity concerns.

    Conclusions:

    • Drug selection for schistosomiasis depends on the schistosome species, patient factors, and risk-benefit assessment.
    • Further research is needed to clarify the long-term implications of certain drugs, such as hycanthone mesylate's mutagenicity.